Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Prolifaron: Panning for antibody gold

The use of phage display technology to generate libraries of antibodies was developed at about the same time by separate groups at the U.K.'s Medical Research Council (MRC) and the Scripps Research Institute in California. While its MRC-derived counterpart, Cambridge Antibody Technology Group plc, has become well-known for the approach, Prolifaron Inc. believes that its application of the technology will be even more useful.

In addition to constructing phage display antibody libraries, Prolifaron develops screening technology, in vitro and in

Read the full 797 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE